165 related articles for article (PubMed ID: 32986499)
1. Developability assessment for monoclonal antibody drug candidates: a case study.
Garripelli VK; Wu Z; Gupta S
Pharm Dev Technol; 2021 Jan; 26(1):11-20. PubMed ID: 32986499
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
[TBL] [Abstract][Full Text] [Related]
3. Matching pH values for antibody stabilization and crystallization suggest rationale for accelerated development of biotherapeutic drugs.
Sjuts H; Schreuder H; Engel CK; Bussemer T; Gokarn Y
Drug Dev Res; 2020 May; 81(3):329-337. PubMed ID: 31758731
[TBL] [Abstract][Full Text] [Related]
4. An accelerated surface-mediated stress assay of antibody instability for developability studies.
Kopp MRG; Wolf Pérez AM; Zucca MV; Capasso Palmiero U; Friedrichsen B; Lorenzen N; Arosio P
MAbs; 2020; 12(1):1815995. PubMed ID: 32954930
[TBL] [Abstract][Full Text] [Related]
5. Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in Silico Tools.
Shan L; Mody N; Sormani P; Rosenthal KL; Damschroder MM; Esfandiary R
Mol Pharm; 2018 Dec; 15(12):5697-5710. PubMed ID: 30395473
[TBL] [Abstract][Full Text] [Related]
6. Biophysical Characterization of Binary Therapeutic Monoclonal Antibody Mixtures.
Krieg D; Berner C; Winter G; Svilenov HL
Mol Pharm; 2020 Aug; 17(8):2971-2986. PubMed ID: 32687367
[TBL] [Abstract][Full Text] [Related]
7. Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection.
Lavoisier A; Schlaeppi JM
MAbs; 2015; 7(1):77-83. PubMed ID: 25514497
[TBL] [Abstract][Full Text] [Related]
8. Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain.
Bauer J; Mathias S; Kube S; Otte K; Garidel P; Gamer M; Blech M; Fischer S; Karow-Zwick AR
MAbs; 2020; 12(1):1787121. PubMed ID: 32658605
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.
Wolf Pérez AM; Lorenzen N; Vendruscolo M; Sormanni P
Methods Mol Biol; 2022; 2313():57-113. PubMed ID: 34478132
[TBL] [Abstract][Full Text] [Related]
10. A novel screening method to assess developability of antibody-like molecules.
Kohli N; Jain N; Geddie ML; Razlog M; Xu L; Lugovskoy AA
MAbs; 2015; 7(4):752-8. PubMed ID: 25961854
[TBL] [Abstract][Full Text] [Related]
11. Five computational developability guidelines for therapeutic antibody profiling.
Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520
[TBL] [Abstract][Full Text] [Related]
12. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.
Khetan R; Curtis R; Deane CM; Hadsund JT; Kar U; Krawczyk K; Kuroda D; Robinson SA; Sormanni P; Tsumoto K; Warwicker J; Martin ACR
MAbs; 2022; 14(1):2020082. PubMed ID: 35104168
[TBL] [Abstract][Full Text] [Related]
13. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.
Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L
MAbs; 2020; 12(1):1743053. PubMed ID: 32249670
[TBL] [Abstract][Full Text] [Related]
14. A high-throughput UPLC method for the characterization of chemical modifications in monoclonal antibody molecules.
Stackhouse N; Miller AK; Gadgil HS
J Pharm Sci; 2011 Dec; 100(12):5115-25. PubMed ID: 21789770
[TBL] [Abstract][Full Text] [Related]
15. Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties.
Svilenov HL; Arosio P; Menzen T; Tessier P; Sormanni P
MAbs; 2023; 15(1):2164459. PubMed ID: 36629855
[TBL] [Abstract][Full Text] [Related]
16. Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.
Majumdar R; Esfandiary R; Bishop SM; Samra HS; Middaugh CR; Volkin DB; Weis DD
MAbs; 2015; 7(1):84-95. PubMed ID: 25524268
[TBL] [Abstract][Full Text] [Related]
17. A comparison of biophysical characterization techniques in predicting monoclonal antibody stability.
Thiagarajan G; Semple A; James JK; Cheung JK; Shameem M
MAbs; 2016; 8(6):1088-97. PubMed ID: 27210456
[TBL] [Abstract][Full Text] [Related]
18. Peptide Optimization at the Drug Discovery-Development Interface: Tailoring of Physicochemical Properties Toward Specific Formulation Requirements.
Evers A; Pfeiffer-Marek S; Bossart M; Heubel C; Stock U; Tiwari G; Gebauer B; Elshorst B; Pfenninger A; Lukasczyk U; Hessler G; Kamm W; Wagner M
J Pharm Sci; 2019 Apr; 108(4):1404-1414. PubMed ID: 30528197
[TBL] [Abstract][Full Text] [Related]
19. Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods.
Makowski EK; Wu L; Gupta P; Tessier PM
MAbs; 2021; 13(1):1895540. PubMed ID: 34313532
[TBL] [Abstract][Full Text] [Related]
20. In Silico Prediction of Diffusion Interaction Parameter (k
Tomar DS; Singh SK; Li L; Broulidakis MP; Kumar S
Pharm Res; 2018 Aug; 35(10):193. PubMed ID: 30128780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
